Her primary areas of investigation include Immunology, Internal medicine, Tissue microarray, Antigen and Colorectal cancer. As part of one scientific family, Lindy G. Durrant deals mainly with the area of Immunology, narrowing it down to issues related to the Cancer, and often Clinical trial. Her Internal medicine research incorporates elements of Endocrinology and Oncology.
Her studies deal with areas such as Cancer research, MHC class I, Survival analysis and Immune system as well as Tissue microarray. Her biological study spans a wide range of topics, including Antibody and Pathology. Her work deals with themes such as Breast cancer, Nottingham Prognostic Index, Angiogenesis and Cytokine, which intersect with Pathology.
Lindy G. Durrant mainly investigates Immunology, Antigen, Antibody, Monoclonal antibody and Immune system. The various areas that Lindy G. Durrant examines in her Immunology study include Cytotoxic T cell and Cancer, Colorectal cancer. Her work carried out in the field of Antigen brings together such families of science as Pathology, Virology and Vaccination.
Her Pathology research focuses on Breast cancer and how it connects with Immunohistochemistry. Her Antibody research integrates issues from Biochemistry and Glycan. Her study looks at the relationship between Immune system and topics such as Cancer research, which overlap with Tissue microarray, Cancer immunotherapy and CD59.
Cancer research, Cancer, Immune system, Antibody and Epitope are her primary areas of study. Lindy G. Durrant has included themes like Enzyme, Colorectal cancer, Ovarian cancer and Cancer immunotherapy in her Cancer research study. Her Cancer study combines topics in areas such as Self-Antigens, Oncology, Glycoprotein and Pathology.
Lindy G. Durrant does research in Antibody, focusing on Monoclonal antibody specifically. Immunology and Antigen are the areas that her Epitope study falls under. The T cell research she does as part of her general Immunology study is frequently linked to other disciplines of science, such as Citrullination, therefore creating a link between diverse domains of science.
Lindy G. Durrant focuses on Epitope, Immunotherapy, Immune system, Immunology and T cell. To a larger extent, Lindy G. Durrant studies Antigen with the aim of understanding Epitope. The Antigen study which covers Cancer that intersects with Adoptive cell transfer, Immunity, Cell and Progression-free survival.
Her research in Immunotherapy intersects with topics in Cancer cell, Antibody and Pharmacology. In Immune system, she works on issues like Cancer research, which are connected to Major histocompatibility complex, Colorectal cancer and Cell nucleus. Her Immunology study frequently links to other fields, such as Autophagy.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.
Nicholas F.S. Watson;Judith M. Ramage;Zahra Madjd;Ian Spendlove.
International Journal of Cancer (2006)
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?
Ekaterina S. Jordanova;Arko Gorter;Ouissam Ayachi;Frans Prins.
Clinical Cancer Research (2008)
Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients
Nicholas F.S. Watson;Nicholas F.S. Watson;Ian Spendlove;Zahra Madjd;Roger McGilvray.
International Journal of Cancer (2006)
NKG2D Ligand Expression in Human Colorectal Cancer Reveals Associations with Prognosis and Evidence for Immunoediting
Roger W. McGilvray;Robert A. Eagle;Nicholas F.S. Watson;Ahmad Al-Attar.
Clinical Cancer Research (2009)
Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer
Jonathan A D Simpson;Ahmad Al-Attar;Nicholas F S Watson;John H Scholefield.
Gut (2010)
Defining the critical hurdles in cancer immunotherapy
Bernard A. Fox;Bernard A. Fox;Dolores J. Schendel;Lisa H. Butterfield;Steinar Aamdal.
Journal of Translational Medicine (2011)
Total loss of MHC class I is an independent indicator of good prognosis in breast cancer
Zahra Madjd;Ian Spendlove;Sarah E. Pinder;Ian O. Ellis.
International Journal of Cancer (2005)
The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin.
S. A. Watson;L. G. Durrant;J. D. Crosbie;D. L. Morris.
International Journal of Cancer (1989)
Gastrin: growth enhancing effects on human gastric and colonic tumour cells.
S Watson;L Durrant;D Morris.
British Journal of Cancer (1989)
Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
Timothy J. Duncan;Ahmad Al-Attar;Phil Rolland;Ian V. Scott.
Clinical Cancer Research (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Nottingham
University of Nottingham
University of Melbourne
University of New South Wales
King's College London
Nottingham Trent University
University of Southampton
University of Nottingham
University of Manchester
University of Nottingham
Technical University of Darmstadt
National University of Singapore
University of Basel
University of Liverpool
Centre national de la recherche scientifique, CNRS
Harvard University
University of Hyogo
University of Guelph
The University of Texas Health Science Center at Houston
Old Dominion University
Ben-Gurion University of the Negev
Columbia University
University of Illinois at Chicago
Karolinska Institute
University of Ferrara
Columbia University